This review emphasizes the critical role of cardio-oncology in identifying shared risk factors and managing cardiovascular toxicities to improve outcomes in the growing population of cancer survivors.
Answers are grounded in this paper and cite their sources.
Cardio-oncology integration may improve cancer survivor outcomes; leaves open optimal surveillance protocols pending prospective trials.
Cardio-oncology is a subspecialty of cardiology. It was created to address oncology data indicating that newly developed drugs for cancer treatment were having unanticipated cardiac side effects. Cardio-oncology designs primary and secondary risk strategies through surveillance as well as interventions to reduce cardiovascular risk (CVR), prevent cardiotoxicities, and manage the side effects that may occur. Rather than discuss in detail the cardiotoxicities of specific therapies or radiation, this review article will explore the interplay of cancer, cancer treatment, and CVR. It will examine the link between CVR and cancer risk, define mechanisms associated with cardiotoxicity, and describe screening and surveillance for patients undergoing cancer treatment. Finally, effective preventative and management strategies used to reduce the incidence of cardiotoxicities in those receiving chemotherapeutics or radiation will be presented.
No takes yet. Share an insight, caveat, or question.
Jessica Shank Coviello (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: